Traders assign an 88.5% probability to no new COVID variant of concern before 2027 because SARS-CoV-2 circulation remains dominated by established Omicron sublineages such as XFG and NB.1.8.1, with no recent WHO or ECDC escalation to VOC status. Genomic surveillance through mid-2026 shows continued evolution among monitored lineages like BA.3.2 and PQ.16.1.1, yet these exhibit limited impact on transmissibility, severity, or immunity compared with prior waves. Updated 2026-2027 monovalent vaccines target current strains like XFG, reflecting stable antigenic profiles rather than abrupt shifts. Low overall case incidence and de-escalated tracking systems further support the consensus that a qualifying new variant is unlikely to emerge in the remaining months of 2026, though ongoing global sequencing could surface surprises.